Klick Health, a global, independent commercialisation partner for life sciences, has acquired Oxford PharmaGenesis, a healthscience communications consultancy.
With the growing importance of converging medical and commercial communications, as healthcare professionals, payers and brands prioritise medical content, and large language models (LLMs) increasingly elevate content from highly authoritative, valued sources, such as peer-reviewed journal articles, Klick and Oxford PharmaGenesis are uniquely equipped with the proven scientific leadership, business models and track records to meet these industry changes head on.
Together, they will focus on helping life sciences clients accelerate their commercial success through complementary medical and commercial strategies, seamless global execution and almost 60 years of combined experience as trusted agency partners.
The move builds on Klick’s continued momentum in the industry and significantly deepens its scientific expertise, notably in therapeutic areas like oncology and rare diseases, while expanding its real-world evidence (RWE) and health economics and outcomes research (HEOR) capabilities.
Leerom Segal, Klick’s Co-Founder and Chairman, said: “We are beyond proud to join forces with Chris…and the entire team at Oxford PharmaGenesis as we focus on helping life sciences clients think holistically about how evidence, medical strategy, access considerations and stakeholder engagement connect across the life cycle with a scientific-to-commercial offering that unlocks the true potential of their innovations.”
Chris Winchester, Oxford PharmaGenesis CEO, said: “Joining Klick Health will ensure that we remain at the cutting edge of healthscience communications but, more importantly, our shared values ensure a bright future together.”